Pfizer Inc.

Revenue declined +41.1% YoY to $59.55B. Net margin at 3.56% (contracting ▼). Return on equity 2.40%, ROA 0.99%, ROIC 0.00%.

• Revenue declined +41.1% YoY to $59.55B.
• Net margin at 3.56% (contracting ▼).
• Return on equity 2.40%, ROA 0.99%, ROIC 0.00%.
• Gross margin 0.00%, operating margin 0.00%.
• Free cash flow margin 8.05% ($4.79B).
• Net income down ▼ +93.2% YoY.
• Debt/equity 0.04, current ratio 1.25, net debt $2.30B.
• Asset turnover 0.29 — capital efficiency.

Latest annual report (10-K) filed Feb 26, 2026. Latest quarterly report (10-Q) filed May 5, 2026. 10 recent 8-K material-event filings in the index.

• Latest annual report (10-K) filed Feb 26, 2026.
• Latest quarterly report (10-Q) filed May 5, 2026.
• 10 recent 8-K material-event filings in the index.
• Recent insider Form 4s: 0 buy vs 0 sell transactions.
• ~10,000+ recent 13F-HR filings reference Pfizer Inc.; broad institutional reporting.
• Recent filers include Axiom Investment Management LLC, Axiom Investment Management LLC, Axiom Investment Management LLC.

7 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. Revenue grew -41.1% but receivables grew -0.9% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.

• Receivables outpacing revenue: Accounts receivable grew -0.9% YoY vs revenue growth of -41.1%. The +40.2% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
• Inventory buildup exceeds sales growth: Inventory grew +6.5% vs revenue -41.1%. Excess inventory may signal weakening demand, potential write-downs, or supply chain overcommitment. Watch gross margin for discounting impact.
• Free cash flow deteriorating: FCF declined +81.6% YoY (from $26.03B to $4.79B). With OCF at $8.70B and capex at $3.91B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
• Going concern doubt: The term "going concern" appears in 23 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
• Material weakness in internal controls: The term "material weakness" appears in 21 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
• NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 6 filing(s).
• Endogenous analysis: Revenue grew -41.1% but receivables grew -0.9% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
• Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
• Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
• 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
• 20 disclosure(s) dropped from prior year — reduced reporting granularity.
• 1 new risk-language term(s) detected in filing text: Substantial doubt about ability to continue.
• Ongoing high-severity risk language: Going concern doubt, Material weakness in internal controls, Restatement of financial statements.